Research programme: COVID 2019 infections vaccine - TScan Therapeutics
Alternative Names: anti-SARS-CoV-2 polyepitope vaccine - TScan Therapeutics; anti-SARS-CoV-2 vaccines - TScan TherapeuticsLatest Information Update: 17 Sep 2021
At a glance
- Originator TScan Therapeutics
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 31 Jul 2021 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral) before July 2021
- 22 Jul 2021 Immunogenicity data from a preclinical trial in COVID-2019 infections released by Tscan therapeutics
- 30 Apr 2021 TScan Therapeutics files provisional patent applications on SARS-CoV-2 technology in USA as of April 2021